SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/21/22 Abiomed Inc. 8-K:8 6/17/22 10:166K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 30K 5: R1 Document and Entity Information HTML 46K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- abmd-20220617_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.LAB XBRL Labels -- abmd-20220617_lab XML 40K 4: EX-101.PRE XBRL Presentations -- abmd-20220617_pre XML 33K 2: EX-101.SCH XBRL Schema -- abmd-20220617 XSD 11K 9: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K 10: ZIP XBRL Zipped Folder -- 0000950170-22-011837-xbrl Zip 12K
8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i June 17, 2022
i ABIOMED, Inc.
(Exact name of Registrant as Specified in Its Charter)
i Delaware |
i 04-2743260 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
i 22 Cherry Hill Drive
i Danvers, i Massachusetts
i 01923
(Address of Principal Executive Offices, including Zip Code)
( i 978) i 646-1400
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol |
Name of each exchange on which registered |
i Common Stock, $0.01 par value |
i ABMD |
i The NASDAQ Stock Market LLC |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
In August 2019, the Company announced that its Board of Directors had authorized the repurchase of up to $200 million of the Company’s common stock. Under this stock repurchase program (“the Program”), the Company is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Securities Exchange Act of 1934. The Program has no expiration date and may be suspended for periods or discontinued at any time. The Company most recently repurchased shares of its common stock pursuant to a 10b5-1 plan which expired on June 30, 2020. Effective June 17, 2022, the Company entered into a new 10b5-1 plan to continue repurchases of the Company’s common stock under the Program.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
ABIOMED, Inc. |
|
|
|
|
|
||
|
|
|
|
By: |
/s/ Marc A. Began |
|
|
|
|
|
Vice President, General Counsel and Secretary |
Date: June 21, 2022 |
|
|
|
|
|
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 6/21/22 | |||
For Period end: | 6/17/22 | |||
6/30/20 | 10-Q, DEF 14A, DEFA14A | |||
List all Filings |